STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Turner, Dan; Ricciuto, Amanda; Lewis, Ayanna; D’Amico, Ferdinando; Dhaliwal, Jasbir; Griffiths, Anne M.; Bettenworth, Dominik; Sandborn, William J.; Sands, Bruce E.; Reinisch, Walter; Schölmerich, Jürgen; Bemelman, Willem A.; Danese, Silvio; Mary, Jean Yves; Rubin, David; Colombel, Jean–Frédéric; Peyrin–Biroulet, Laurent; Dotan, Iris; Abreu, María T.; Dignaß, Axel

doi:10.1053/j.gastro.2020.12.031

Cited by 1,145 publications

(992 citation statements)

References 86 publications

(66 reference statements)

Supporting

Mentioning

951

Contrasting

Unclassified

Order By: Relevance

“…The treat-to-target strategy requires frequent monitoring of disease activity. Recently updated STRIDE-II statements have mentioned that the most important long-term achievable treatment targets for IBD patients are clinical remission, endoscopic healing, restoration of quality of life, and absence of disability [ 4 ]. Colonoscopy is also the current gold standard for monitoring mucosal healing in IBD patients [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

et al. 2021

View full text Add to dashboard Cite

Background This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). Methods Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn’s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC. Results A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4 ± 12.6 μg/ml at week 0, 15.5 ± 7.7 μg/ml at week 12, 15.7 ± 9.6 μg/ml at week 24, and 14.5 ± 6.8 μg/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD: r = 0.391 at week 0, r = 0.563 at week 24, r = 0.697 at week 52; MES: r = 0.534 at week 0, r = 0.429 at week 12, r = 0.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426). Conclusions Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…From review of the literature, it is clear that effective treatment of moderate-to-severe ulcerative colitis can restore QoL and return it to normal or near normal levels [45 , 47] . This has been further indicated by the recent STRIDE-II survey, which confirmed that meeting therapeutic goals with a treat-to-target strategy can restore QoL [7] . Biological therapies have shown improvement in the QoL of patients with ulcerative colitis during the induction phase, with benefits that are maintained during maintenance treatment [45 , 47] .…”

Section: Discussionmentioning

confidence: 66%

“…endoscopic and histologic remission). Towards this end, therapeutic targets that can affect the natural history of the disease and improve the patient's quality of life (QoL) have been established [6] and are continuously refined according to the most recent evidence [7] . These include more detailed mucosal healing criteria and use of biomarkers such as fecal calprotectin.…”

Section: Introductionmentioning

confidence: 99%

Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review

Armuzzi

Liguori

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

As a chronic inflammatory disease, ulcerative colitis has significant negative impact on the quality of life (QoL) of patients. Since the disease affects many aspects of QoL, comprising multiple domains, treatments that induce and maintain remission can provide benefits beyond hard clinical endpoints. Effective treatment of ulcerative colitis can restore QoL and return it to normal or near normal levels. Biological therapies have shown consistent improvement in the QoL of patients with ulcerative colitis during the induction phase, with benefits that are generally maintained in the long-term. Current medical treatment options broadly comprise aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors, as well as biologic therapies. Conventional therapies do not always adequately control disease in a sizeable portion of patients, while anti-TNF antibodies are associated with several issues such as contraindications, intolerance, primary non-response, and loss of response in some patients. JAK inhibitors have been associated with clinical improvements in disease manifestations and long-term improvement in QoL outcomes. However, additional studies are needed to better understand the comparative effects of different treatments on QoL and patient preferences for therapy. Herein, the available evidence is reviewed regarding the impact of various treatments on QoL in patients with moderate to severe ulcerative colitis.

show abstract

“…Endoscopic response is defined as a decrease greater than 50% in SES-CD or CDEIS[ 19 ] (Figure 1 ). STRIDE-II maintained endoscopic criteria for UC and CD[ 20 ].…”

Section: Endoscopy To Assess Disease Activitymentioning

confidence: 99%

Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis

Núñez¹,

Cleveland²,

Quera³

et al. 2021

WJG

View full text Add to dashboard Cite

Inflammatory bowel disease, encompassing Crohn’s disease (CD) and ulcerative colitis, are chronic immune-mediated inflammatory bowel diseases (IBD) that primarily affect the gastrointestinal tract with periods of activity and remission. Large body of evidence exist to strengthen the prognostic role of endoscopic evaluation for both disease activity and severity and it remains the gold standard for the assessment of mucosal healing. Mucosal healing has been associated with improved clinical outcomes with prolonged remission, decreased hospitalization, IBD-related surgeries and colorectal cancer risk. Therefore, endoscopic objectives in IBD have been incorporated as part of standard care. With the known increased risk of colorectal cancer in IBD, although prevention strategies continue to develop, regular surveillance for early detection of neoplasia continue to be paramount in IBD patients’ care. It is thanks to evolving technology and visualization techniques that surveillance strategies are continuously advancing. Therapeutic endoscopic options in IBD have also been expanding, from surgery sparing therapies such as balloon dilation of fibrostenotic strictures in CD to endoscopic mucosal resection of neoplastic lesions. In this review article, we discuss the current evidence on the use of endoscopy as part of standard of care of IBD, its role in surveillance of neoplasia, and the role of interventional endoscopic therapies.

show abstract

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Cited by 1,145 publications

References 86 publications

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review

Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis

Contact Info

Product

Resources

About